You just read:

INOVIO's INO-5401 in Combination with PD-1 Inhibitor Libtayo® (cemiplimab) Demonstrates 85% of Newly Diagnosed Glioblastoma Patients Are Alive 12 Months Following Treatment

News provided by

INOVIO Pharmaceuticals, Inc.

May 14, 2020, 07:00 ET